Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2106-2113

  Kim, Seoyoung C ^a   Schneeweiss, Sebastian ^a   Liu, Jun ^a   Karlson, Elizabeth W ^a   Katz, Jeffrey N ^a   Feldman, Sarah ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ADULT; ALGORITHM; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLPOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROPENSITY SCORE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; UTERUS BIOPSY; UTERUS SURGERY;

EID: 84983565613     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39689     Document Type: Article

References (36)

1. Health OrganizationURLGLOBOCAN 2012 v1.1: estimated cancer incidence, mortality, and prevalence worldwide in 2012. International Agency for Research on Cancer: World : http://globocan.iarc.fr.
2. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187–93.
3. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am 2008;35:519–36.
4. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautière JL, Carbillet JP, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396–403.
5. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006;12:6167–71.
6. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008;103:631–6.
7. Rojo Contreras W, Montoya Fuentes H, Gamez Nava JI, Suárez Rincón AE, Vázquez Salcedo J, Padilla Rosas M, et al. Prevalence and cervical human papilloma virus associated factors in patients with rheumatoid arthritis. Ginecol Obstet Mex 2008;76:9–17. In Spanish.
8. Santana IU, Gomes Ado N, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 2011;30:665–72.
9. Tam LS, Chan PK, Ho SC, Yu MY, Yim SF, Cheung TH, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2011;63:269–76.
10. Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, Montoya-Fuentes H, Trujillo-Hernandez B, Trujillo X, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012;21:365–72.
11. Strickler H, Burk R, Fazzari M, Anastos K, Minkoff H, Massad LS, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005;97:577–86.
12. Garcia-Pineres A, Hildesheim A, Herrero R, Trivett M, Williams M, Atmetlla I, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res 2006;66:11070–6.
13. Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J infect Chemother 2012;18:807–15.
14. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012;25:215–22.
15. Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2015;74:1360–7.
16. Wadström H, Frisell T, Askling J. Cervical dysplasia and cervical cancer in women with rheumatoid arthritis. Ann Rheum Dis 2015;74 Suppl 2:441.
17. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015;17:212.
18. Mercer LK, Low AS, Galloway JB, Watson KD, Lunt M, Symmons DP, et al, on behalf of the BSRBR Control Center Consortium. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix [letter]. Ann Rheum Dis 2013;72:143–4.
19. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, Kimmel SE, editors. Textbook of pharmacoepidemiology. Philadelphia: John Wiley & Sons; 2006. p. 167–72.
20. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915–20.
21. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
22. Kim SC, Gillet VG, Feldman S, Lii H, Toh S, Brown JS, et al. Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf 2013;22:1239–44.
23. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749–59.
24. Mangione-Smith R, McGlynn EA, Hiatt L. Screening for chlamydia in adolescents and young women. Arch Pediatr Adolesc Med 2000;154:1108–13.
25. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757–63.
26. Austin PC. The performance of different propensity score methods for estimating marginal odds ratios. Stat Med 2007;26:3078–94.
27. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009;51:171–84.
28. Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption. In: Gail M, Krickberg K, Samet J, Tsiatis A, Wong W, editors. Survival analysis: a self-learning text. 3rd ed. New York: Springer 2012.
29. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ, 2001. p. 285–312.
30. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010;6:165–74.
31. Feldman CH, Hiraki LT, Lii H, Seeger JD, Kim SC. Human papillomavirus vaccine uptake among individuals with systemic inflammatory diseases. PloS One 2015;10:e0117620.
32. Centers for Disease Control and Prevention. Teen vaccination coverage: 2014 National Immunization Survey (NIS-Teen). URL: http://www.cdc.gov/vaccines/who/teens/vaccination-coverage.html.
33. Kim SC, Schneeweiss S, Myers JA, Liu J, Solomon DH. No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum 2012;64:3076–82.
34. Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2015;64:300–4.
35. US Preventive Services Task Force. Final update summary. Cervical cancer: screening. March 2012. URL: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/cervical-cancer-screening.
36. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437–41.